×
About 119,188 results

ALLMedicine™ Rheumatoid Arthritis Center

Research & Reviews  51,275 results

Biologics and atherosclerotic cardiovascular risk in rheumatoid arthritis: a review of ...
https://doi.org/10.1080/1744666X.2021.1899809
Expert Review of Clinical Immunology; Karpouzas GA, Bui VL et. al.

Mar 6th, 2021 - Cardiovascular disease is a leading comorbidity in rheumatoid arthritis. Timely introduction of biologic therapies in a treat-to target approach has optimized disease-related outcomes and attenuated accrual of comorbidities, including cardiovascul...

Strategies for developing and implementing a rheumatoid arthritis healthcare quality fr...
https://doi.org/10.1136/bmjopen-2020-043759
BMJ Open; Barber C, Lacaille D et. al.

Mar 6th, 2021 - To obtain stakeholder perspectives to inform the development and implementation of a rheumatoid arthritis (RA) healthcare quality measurement framework. Qualitative study using thematic analysis of focus groups and interviews. Arthritis stakeholde...

The gut-joint axis in rheumatoid arthritis.
https://doi.org/10.1038/s41584-021-00585-3 10.1001/jama.2018.13103 10.1186/s40168-016-0206-x 10.7554/eLife.01202 10.1038/s41584-018-0070-0 10.1016/S2665-9913(20)30064-3 10.1038/nm.3914 10.1186/s13073-016-0299-7 10.1002/art.39785 10.1002/art.39783 10.1136/annrheumdis-2018-214514 10.1136/annrheumdis-2019-216565 10.1136/annrheumdis-2019-216637 10.3390/jcm8050693 10.1038/mi.2008.17 10.1038/nri.2017.7 10.1002/art.39226 10.1016/j.berh.2020.101497 10.1016/j.biocel.2017.06.013 10.1038/nrrheum.2017.132 10.1093/rheumatology/kez368 10.1155/2017/4835189 10.1177/2050640619867555 10.1038/s41598-017-15802-x 10.1002/art.40490 10.1038/s41401-019-0279-8 10.1073/pnas.0909122107 10.1038/srep37276 10.1038/s41467-019-09361-0 10.1016/j.immuni.2010.06.001 10.1016/j.cell.2009.09.033 10.1038/nature07240 10.1084/jem.191.2.313 10.1172/JCI32639 10.1186/s40168-017-0278-2 10.1111/apm.12399 10.1002/art.40003 10.3390/jcm8111770 10.1136/annrheumdis-2018-213724 10.1038/mi.2015.121 10.1016/j.immuni.2013.08.013 10.1016/j.jaut.2020.102420 10.1016/j.clim.2015.04.016 10.1371/journal.pone.0036095 10.1038/s41598-020-72441-5 10.1002/art.22213 10.1016/j.jaut.2009.12.007 10.3389/fcimb.2019.00369 10.1126/science.1195568 10.1038/nrmicro2974 10.1038/s41467-018-07359-8 10.1016/j.cell.2011.04.022 10.1016/j.ebiom.2019.10.002 10.1038/s41467-020-15831-7 10.1038/srep30594 10.1136/annrheumdis-2015-208025 10.1136/ard.2010.149229 10.1053/gast.1996.v110.pm8964393 10.1136/annrheumdis-2014-206323 10.1002/art.40582 10.1126/scitranslmed.aaf9655 10.1136/ard.2003.011304 10.3109/03009749709115825 10.1080/14397595.2016.1211229 10.1093/rheumatology/keaa133 10.1126/science.aar7201 10.1038/s41575-019-0248-1 10.1371/journal.pone.0170034 10.12688/f1000research.20510.1 10.1016/j.cgh.2012.08.012 10.4049/jimmunol.176.4.2512 10.1136/gut.52.2.218 10.1080/21688370.2016.1251384 10.1080/00365520500235334 10.1136/annrheumdis-2016-210000 10.1053/gast.2002.36578 10.1002/art.40657 10.1038/s41598-017-07196-7 10.1172/jci.insight.125191 10.1038/srep04828 10.1371/journal.pone.0134234 10.1186/ar2388 10.1093/rheumatology/40.10.1175 10.1053/j.gastro.2008.03.023 10.1371/journal.pone.0211436 10.3109/03009748309102897 10.1093/rheumatology/26.2.103 10.1016/S0140-6736(84)92739-9 10.1136/gut.43.4.506 10.1152/ajpcell.00397.2009 10.1016/j.immuni.2016.03.013 10.1002/art.20018 10.1002/art.11223 10.1136/annrheumdis-2013-204154 10.1002/art.34344 10.1007/s10067-009-1128-9 10.1002/art.21575 10.1016/S1297-319X(03)00063-0 10.1136/ard.2005.045229 10.1007/BF00918681 10.1002/art.41091 10.1136/gut.2005.076901 10.1084/jem.181.1.137 10.1053/gast.2000.20173 10.1136/ard.56.2.130 10.1007/s11926-019-0834-9 10.1016/j.immuni.2016.11.005 10.1016/S1074-7613(00)80371-4 10.1084/jem.20140678 10.1016/j.berh.2020.101493 10.3389/fimmu.2017.01909 10.1038/s41598-017-02729-6 10.1016/j.immuni.2019.09.014 10.4049/jimmunol.1700596 10.1002/art.40150 10.1002/art.39811 10.1186/s13075-020-2115-4 10.1186/s13075-019-1984-x 10.3899/jrheum.101377 10.1038/s41577-019-0191-y 10.1136/rmdopen-2018-000821 10.1136/annrheumdis-2015-208902 10.1186/s13075-018-1799-1 10.1182/blood-2012-07-445429 10.4049/jimmunol.1302701 10.1016/j.cyto.2017.07.007 10.1038/cti.2016.51 10.1186/1471-213X-9-49 10.1038/sj.embor.7400361 10.1016/j.immuni.2014.10.010 10.3389/fimmu.2019.00411 10.1016/j.immuni.2017.06.020 10.1002/art.23437 10.1016/j.semarthrit.2020.06.021 10.1016/j.molimm.2020.06.003 10.4049/jimmunol.2000663 10.1073/pnas.93.24.14014 10.1128/mBio.01693-15 10.1186/ar492 10.3390/ijms19102938 10.1038/nature25979 10.1016/S0021-9258(18)33497-5 10.1038/s41584-020-0395-3 10.3109/00365528109182016 10.1038/nrrheum.2016.68 10.1093/rheumatology/26.5.334 10.1093/rheumatology/33.11.1039 10.1111/1756-185X.13802 10.1186/s40168-018-0603-4 10.1007/s10787-017-0436-y 10.1136/ard.62.3.208 10.1016/0140-6736(91)91770-U 10.1126/science.1241165 10.3390/nu11102392 10.1038/srep32928 10.1007/s10067-018-4080-8 10.1002/JLB.3A1218-476RR 10.4049/jimmunol.1601776 10.3389/fimmu.2011.00025 10.1186/s40168-015-0097-2 10.1073/pnas.1617460113 10.1038/nature17655 10.1136/annrheumdis-2016-211064 10.1136/annrheumdis-2019-215743
Nature Reviews. Rheumatology; Zaiss MM, Joyce Wu HJ et. al.

Mar 6th, 2021 - Rheumatoid arthritis (RA) is a chronic autoimmune inflammatory disorder that primarily affects the joints. One hypothesis for the pathogenesis of RA is that disease begins at mucosal sites as a consequence of interactions between the mucosal immun...

see more →

Guidelines  235 results

Similar Impact of Psoriatic Arthritis and Rheumatoid Arthritis on Objective and Subjective Parameters of Hand Function
https://onlinelibrary.wiley.com/doi/10.1002/acr2.11196
ACR Open Rheumatology; Liphardt AM

Nov 24th, 2020 - The objective of this study was to compare the impact of psoriatic disease (psoriatic arthritis [PsA] and psoriasis) and rheumatoid arthritis (RA) on objective and subjective parameters of hand function.

ACR Convergence 2020: Study Data for Lupus & Rheumatoid Arthritis
https://www.the-rheumatologist.org/article/acr-convergence-2020-study-data-for-lupus-rheumatoid-arthritis/
The Rheumatologist; Hickman RJ.

Nov 8th, 2020 - At the annual meeting’s second Plenary Session, Saturday, Nov. 7, speakers highlighted phase 2 results of a potential new biologic for systemic lupus erythematosus (SLE), as well as data on remission maintenance in rheumatoid arthritis (RA) after ...

ACR RA guidelines ‘push the needle away’ from glucocorticoids as primary option
https://www.healio.com/news/rheumatology/20201109/acr-ra-guidelines-push-the-needle-away-from-glucocorticoids-as-primary-option

Nov 7th, 2020 - Glucocorticoids should no longer be the “default” option for many patients with rheumatoid arthritis, according to authors of a new recommendation document presented at ACR Convergence 2020.

Cardiac adverse events associated with chloroquine and hydroxychloroquine exposure in 20 years of drug safety surveillance reports
https://pubmed.ncbi.nlm.nih.gov/33154498/
Scientific Reports; Cohen IV, Makunts T et. al.

Nov 4th, 2020 - Chloroquine (CQ) and hydroxychloroquine (HCQ) are on the World Health Organization's List of Essential Medications for treating non-resistant malaria, rheumatoid arthritis (RA) and systemic lupus erythematosus (SLE). In addition, both drugs are cu...

Machine Learning Could Benefit Rheumatoid Arthritis Treatment with Sarilumab
https://www.hcplive.com/view/machine-learning-benefit-rheumatoid-arthritis-treatment-sarilumab

Nov 2nd, 2020 - As interleukin receptor (IL) inhibitors, the monoclonal antibody drug class has come to revolutionize fields of inflammatory disease care, though the utility and resourcing of such promising agents is yet to be fully refined. Namely, clinicians ca...

see more →

Drugs  3,235 results see all →

Clinicaltrials.gov  58,301 results

Biologics and atherosclerotic cardiovascular risk in rheumatoid arthritis: a review of ...
https://doi.org/10.1080/1744666X.2021.1899809
Expert Review of Clinical Immunology; Karpouzas GA, Bui VL et. al.

Mar 6th, 2021 - Cardiovascular disease is a leading comorbidity in rheumatoid arthritis. Timely introduction of biologic therapies in a treat-to target approach has optimized disease-related outcomes and attenuated accrual of comorbidities, including cardiovascul...

Strategies for developing and implementing a rheumatoid arthritis healthcare quality fr...
https://doi.org/10.1136/bmjopen-2020-043759
BMJ Open; Barber C, Lacaille D et. al.

Mar 6th, 2021 - To obtain stakeholder perspectives to inform the development and implementation of a rheumatoid arthritis (RA) healthcare quality measurement framework. Qualitative study using thematic analysis of focus groups and interviews. Arthritis stakeholde...

The gut-joint axis in rheumatoid arthritis.
https://doi.org/10.1038/s41584-021-00585-3 10.1001/jama.2018.13103 10.1186/s40168-016-0206-x 10.7554/eLife.01202 10.1038/s41584-018-0070-0 10.1016/S2665-9913(20)30064-3 10.1038/nm.3914 10.1186/s13073-016-0299-7 10.1002/art.39785 10.1002/art.39783 10.1136/annrheumdis-2018-214514 10.1136/annrheumdis-2019-216565 10.1136/annrheumdis-2019-216637 10.3390/jcm8050693 10.1038/mi.2008.17 10.1038/nri.2017.7 10.1002/art.39226 10.1016/j.berh.2020.101497 10.1016/j.biocel.2017.06.013 10.1038/nrrheum.2017.132 10.1093/rheumatology/kez368 10.1155/2017/4835189 10.1177/2050640619867555 10.1038/s41598-017-15802-x 10.1002/art.40490 10.1038/s41401-019-0279-8 10.1073/pnas.0909122107 10.1038/srep37276 10.1038/s41467-019-09361-0 10.1016/j.immuni.2010.06.001 10.1016/j.cell.2009.09.033 10.1038/nature07240 10.1084/jem.191.2.313 10.1172/JCI32639 10.1186/s40168-017-0278-2 10.1111/apm.12399 10.1002/art.40003 10.3390/jcm8111770 10.1136/annrheumdis-2018-213724 10.1038/mi.2015.121 10.1016/j.immuni.2013.08.013 10.1016/j.jaut.2020.102420 10.1016/j.clim.2015.04.016 10.1371/journal.pone.0036095 10.1038/s41598-020-72441-5 10.1002/art.22213 10.1016/j.jaut.2009.12.007 10.3389/fcimb.2019.00369 10.1126/science.1195568 10.1038/nrmicro2974 10.1038/s41467-018-07359-8 10.1016/j.cell.2011.04.022 10.1016/j.ebiom.2019.10.002 10.1038/s41467-020-15831-7 10.1038/srep30594 10.1136/annrheumdis-2015-208025 10.1136/ard.2010.149229 10.1053/gast.1996.v110.pm8964393 10.1136/annrheumdis-2014-206323 10.1002/art.40582 10.1126/scitranslmed.aaf9655 10.1136/ard.2003.011304 10.3109/03009749709115825 10.1080/14397595.2016.1211229 10.1093/rheumatology/keaa133 10.1126/science.aar7201 10.1038/s41575-019-0248-1 10.1371/journal.pone.0170034 10.12688/f1000research.20510.1 10.1016/j.cgh.2012.08.012 10.4049/jimmunol.176.4.2512 10.1136/gut.52.2.218 10.1080/21688370.2016.1251384 10.1080/00365520500235334 10.1136/annrheumdis-2016-210000 10.1053/gast.2002.36578 10.1002/art.40657 10.1038/s41598-017-07196-7 10.1172/jci.insight.125191 10.1038/srep04828 10.1371/journal.pone.0134234 10.1186/ar2388 10.1093/rheumatology/40.10.1175 10.1053/j.gastro.2008.03.023 10.1371/journal.pone.0211436 10.3109/03009748309102897 10.1093/rheumatology/26.2.103 10.1016/S0140-6736(84)92739-9 10.1136/gut.43.4.506 10.1152/ajpcell.00397.2009 10.1016/j.immuni.2016.03.013 10.1002/art.20018 10.1002/art.11223 10.1136/annrheumdis-2013-204154 10.1002/art.34344 10.1007/s10067-009-1128-9 10.1002/art.21575 10.1016/S1297-319X(03)00063-0 10.1136/ard.2005.045229 10.1007/BF00918681 10.1002/art.41091 10.1136/gut.2005.076901 10.1084/jem.181.1.137 10.1053/gast.2000.20173 10.1136/ard.56.2.130 10.1007/s11926-019-0834-9 10.1016/j.immuni.2016.11.005 10.1016/S1074-7613(00)80371-4 10.1084/jem.20140678 10.1016/j.berh.2020.101493 10.3389/fimmu.2017.01909 10.1038/s41598-017-02729-6 10.1016/j.immuni.2019.09.014 10.4049/jimmunol.1700596 10.1002/art.40150 10.1002/art.39811 10.1186/s13075-020-2115-4 10.1186/s13075-019-1984-x 10.3899/jrheum.101377 10.1038/s41577-019-0191-y 10.1136/rmdopen-2018-000821 10.1136/annrheumdis-2015-208902 10.1186/s13075-018-1799-1 10.1182/blood-2012-07-445429 10.4049/jimmunol.1302701 10.1016/j.cyto.2017.07.007 10.1038/cti.2016.51 10.1186/1471-213X-9-49 10.1038/sj.embor.7400361 10.1016/j.immuni.2014.10.010 10.3389/fimmu.2019.00411 10.1016/j.immuni.2017.06.020 10.1002/art.23437 10.1016/j.semarthrit.2020.06.021 10.1016/j.molimm.2020.06.003 10.4049/jimmunol.2000663 10.1073/pnas.93.24.14014 10.1128/mBio.01693-15 10.1186/ar492 10.3390/ijms19102938 10.1038/nature25979 10.1016/S0021-9258(18)33497-5 10.1038/s41584-020-0395-3 10.3109/00365528109182016 10.1038/nrrheum.2016.68 10.1093/rheumatology/26.5.334 10.1093/rheumatology/33.11.1039 10.1111/1756-185X.13802 10.1186/s40168-018-0603-4 10.1007/s10787-017-0436-y 10.1136/ard.62.3.208 10.1016/0140-6736(91)91770-U 10.1126/science.1241165 10.3390/nu11102392 10.1038/srep32928 10.1007/s10067-018-4080-8 10.1002/JLB.3A1218-476RR 10.4049/jimmunol.1601776 10.3389/fimmu.2011.00025 10.1186/s40168-015-0097-2 10.1073/pnas.1617460113 10.1038/nature17655 10.1136/annrheumdis-2016-211064 10.1136/annrheumdis-2019-215743
Nature Reviews. Rheumatology; Zaiss MM, Joyce Wu HJ et. al.

Mar 6th, 2021 - Rheumatoid arthritis (RA) is a chronic autoimmune inflammatory disorder that primarily affects the joints. One hypothesis for the pathogenesis of RA is that disease begins at mucosal sites as a consequence of interactions between the mucosal immun...

see more →

News  5,993 results

Glucocorticoids Linked to Higher Mortality Rates in Patients with RA and Diabetes
https://www.medscape.com/viewarticle/946930

Mar 4th, 2021 - Takeaway Glucocorticoid (GC) use was associated with higher mortality rates in patients with rheumatoid arthritis (RA) and concomitant type 2 diabetes (T2D) vs patients with RA who did not have T2D, despite apparently reassuring similar relative r...

RA Experts Highlight Key Developments Over the Past Year
https://www.medscape.com/viewarticle/946955

Mar 4th, 2021 - A massive Swedish cohort study suggesting that biologic agents reduce the known excess risk of lymphoma in patients with rheumatoid arthritis was hailed as one of the high points of the last year by speakers at the 2021 Rheumatology Winter Clinica...

Micromotors Promising for Rheumatoid Arthritis Therapy
https://www.medscape.com/viewarticle/946834

Mar 3rd, 2021 - NEW YORK (Reuters Health) - Magnesium-based micromotors showed promise as a delivery system for hydrogen therapy to inflamed joints in an experimental model of rheumatoid arthritis, researchers say. Hydrogen gas has been shown to neutralize overpr...

Physical Activity in People with RA Starting Methotrexate Therapy
https://www.medscape.com/viewarticle/946512

Feb 25th, 2021 - Takeaway Majority of people with rheumatoid arthritis (RA) reported some physical activity (PA) when starting methotrexate (MTX); 28% of participants performed no PA when starting MTX. 10% of those performing PA when starting MTX stopped over the ...

Methotrexate-Associated Hepatotoxicity Risk Differs Between Psoriasis, PsA, and RA Patients
https://www.medscape.com/viewarticle/946521

Feb 25th, 2021 - Patients taking methotrexate for psoriasis or psoriatic arthritis (PsA) were at a higher risk of developing liver disease than were patients with rheumatoid arthritis (RA) on methotrexate, in a large population-based study published in the Journal...

see more →

Patient Education  149 results see all →